For the quarter ended December 2025, ICU Medical (ICUI) reported revenue of $535.94 million, down 13.8% over the same period last year. EPS came in at $1.91, compared to $2.11 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $528.97 million, representing a surprise of +1.32%. The company delivered an EPS surprise of +13.52%, with the consensus EPS estimate being $1.68.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how ICU Medical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Infusion Systems: $176.3 million compared to the $177.59 million average estimate based on two analysts.
- Revenue- Vital Care: $79.7 million compared to the $76.87 million average estimate based on two analysts.
- Revenue- Consumables: $284.7 million versus the two-analyst average estimate of $280.64 million.
View all Key Company Metrics for ICU Medical here>>>
Shares of ICU Medical have returned -2.3% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ICU Medical, Inc. (ICUI): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
